Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•13/11/2026•09:03 ET
0
Key Highlights
- ➤SIL204 first patient dosed in Phase 2/3 pancreatic cancer trial
- ➤Third-quarter financings raised approximately $5.24 million gross proceeds
- ➤Cash and equivalents $4.8 million; shareholders’ equity approximately $3.0 million
- ➤Nine-month net loss $8.8 million, up 17.3% year over year
- ➤Company enacted a 1-for-24 reverse share split November 10, 2026
Expert Statements
Ilan Hadar, Chairman and Chief Executive Officer of Silexion
“In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September. At the same time, our laboratory work continued to strengthen the case for SIL204, with new data suggesting it may help the immune system recognize cancer cells, and showing that it uses natural carriers in the blood to enter cancer cells. Our focus now is on enrolling the first group of patients and bringing more hospitals in Israel and Germany into the trial.”
Mirit Horenshtein Hadar, Chief Financial Officer of Silexion
“During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market facility, increasing our cash and cash equivalents to $4.8 million and shareholders’ equity to approximately $3.0 million as of September 30, 2026. This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll patients in the Phase 2/3 trial.”
First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment
New translational data expanded SIL204’s profile, including a coordinated immune-sensitization signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism that supports systemic administration
Get started
Create a free account to read the full story.